Search results
Results from the WOW.Com Content Network
Vancomycin. Six different types of vancomycin resistance are shown by enterococcus: Van-A, Van-B, Van-C, Van-D, Van-E and Van-G. [4] The significance is that Van-A VRE is resistant to both vancomycin and teicoplanin, [5] Van-B VRE is resistant to vancomycin but susceptible to teicoplanin, [6] [7] and Van-C is only partly resistant to vancomycin.
Enterococcus faecium has been a leading cause of multi-drug resistant enterococcal infections over Enterococcus faecalis in the United States. Approximately 40% of medical intensive care units reportedly found that the majority, respectively 80% and 90.4%, of device-associated infections (namely, infections due to central lines, urinary drainage catheters, and ventilators) were due to ...
Dalbavancin also shows in vitro activity against vancomycin-susceptible Enterococcus faecium and Enterococcus faecalis. [3] Other Gram-positive organisms belonging to the Bacillus spp., Listeria spp., and Corynebacterium spp. may show in vitro susceptibility, and dalbavancin may exhibit activity against enterococci expressing the VanB or VanC ...
The antibiotic, rifaximin, has enabled the global emergence of vancomycin-resistant enterococcus faecium, or VRE, a superbug that frequently causes serious infections in hospitalised patients ...
Linezolid is an antibiotic used for the treatment of infections caused by Gram-positive bacteria that are resistant to other antibiotics. [9] [10] Linezolid is active against most Gram-positive bacteria that cause disease, including streptococci, vancomycin-resistant enterococci (VRE), and methicillin-resistant Staphylococcus aureus (MRSA).
Quinupristin and dalfopristin are protein synthesis inhibitors in a synergistic manner. While each of the two is only a bacteriostatic agent, the combination shows bactericidal activity.
Synercid (weight-to-weight ratio of 30% quinupristin to 70% dalfopristin) is used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. [ 3 ] Synthesis
Vancomycin non-susceptible isolates of Staph aureus have been isolated in Asia and the United States. [27] A study performed in 1992 demonstrated that Vancomycin resistance could be transferred from Enterococcus faecalis/faecium to Staph aureus through the transfer of the VanA and VanB genes. [28]